April 25

Product Overview

Avil 25 is an antihistamine medication containing Pheniramine as its active ingredient, available in tablet form. This first-generation antihistamine is clinically proven to effectively alleviate symptoms of allergic reactions including pruritus (itching), rhinorrhea (runny nose), lacrimation (watery eyes), and sneezing. By competitively blocking H1 histamine receptors, Avil 25 inhibits the physiological effects of histamine release during allergic responses, providing rapid symptomatic relief for various hypersensitivity conditions.

Therapeutic Indications

Avil 25 is indicated for the management of:
– Allergic rhinoconjunctivitis (seasonal/perennial)
– Allergic contact dermatitis
– Urticaria (acute/chronic)
– Angioneurotic edema
– Pruritic dermatoses
– Hypersensitivity reactions to insect bites/stings
– Anaphylactic adjunct therapy (as part of comprehensive treatment)

Administration Guidelines

For optimal therapeutic outcomes:
1. Administer orally with 200-250mL water
2. Standard dosing: 2-3 divided doses daily
3. Maximum daily dose: 75mg (adults); 1mg/kg (pediatric)
4. Preferably administer postprandially to minimize GI irritation
5. Tablets should be swallowed whole without crushing/chewing
6. Adjust dosage in hepatic/renal impairment per physician guidance

Mechanism of Action

Pheniramine maleate exerts its therapeutic effects through:
– Competitive antagonism at H1 histamine receptors
– Inhibition of histamine-mediated vasodilation
– Reduction of capillary permeability
– Anticholinergic activity (muscarinic receptor blockade)
– Mild sedative effects via central histamine receptor blockade

Posology

Standard dosing regimen:
– Adults: 25-50mg every 4-6 hours (max 75mg/day)
– Children >6 years: 12.5-25mg every 6-8 hours
– Geriatric patients: Initiate with lower doses
– Hepatic impairment: Dose reduction required
Note: Always individualize therapy based on clinical response and tolerability

Therapeutic Advantages

Clinical benefits include:
– Rapid onset of action (30-60 minutes)
– Extended duration of effect (4-6 hours)
– Effective symptomatic control of Type I hypersensitivity
– Cost-effective therapeutic option
– Convenient oral dosage form
– Established safety profile

Adverse Effects

Common (≥1/100 to <1/10): - Somnolence - Xerostomia - Mild blurred vision - Gastrointestinal discomfort - Fatigue Less frequent: - Urinary retention - Tachycardia - Paradoxical excitation (pediatric patients) - Photosensitivity reactions Precautions

Special populations requiring monitoring:
– Patients with narrow-angle glaucoma
– BPH patients
– Cardiovascular disorders
– Epilepsy/seizure disorders
– Hepatic impairment
– Pregnancy category B (use only if clearly needed)
– Lactation: Excreted in breast milk

Storage Conditions

Optimal storage parameters:
– Temperature: 15-30°C
– Humidity: <60% RH - Protection from light exposure - Original packaging until use - Shelf life: 36 months from manufacture - Keep in child-resistant container Disclaimer:

This product information is intended for healthcare professionals. The content represents current medical knowledge but may not encompass all possible clinical situations. Prescribing decisions should be based on professional judgment considering individual patient factors. Report any adverse events to the appropriate regulatory authority. This information does not replace direct medical supervision.